Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer ValidGlobeNewsWire • 02/03/22
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of CatalystGlobeNewsWire • 01/28/22
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for RehearingGlobeNewsWire • 01/10/22
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in JapanGlobeNewsWire • 12/06/21
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/15/21
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 30%Zacks Investment Research • 11/15/21
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Catalyst (CPRX) Is a Great Choice for "Trend" Investors, Here's WhyZacks Investment Research • 11/04/21
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to DeclineZacks Investment Research • 11/02/21
4 Small Drug Stocks That Hold Promise Despite Industry ChallengesZacks Investment Research • 10/27/21
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021GlobeNewsWire • 10/25/21
Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?Zacks Investment Research • 10/08/21
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMSGlobeNewsWire • 09/30/21
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewsWire • 09/17/21